Biography of Robert Langer | |
|
Founder of 40 different companies, among them: Moderna, Inc., Momenta Pharmaceuticals, Inc. and Seer, Inc. (California), Robert S. Langer is an entrepreneur is Professor at Massachusetts Institute of Technology, Specialists at The Water Initiative LLC and Professor at David H. Koch Institute for Integrative Cancer Research and on the board of 31 other companies.
In the past he was Director at Combinent BioMedical Systems, Inc. (he founded the company in 2009), Board Advisor at Celero Systems, Inc. (he founded the company), Chairman-Science Board at US Food & Drug Administration, Member of National Academy of Sciences, Member of National Academy of Engineering, Member of Institute of Medicine, Director at Momenta Pharmaceuticals, Inc., Director at Pervasis Therapeutics, Inc., Director at DNIB Unwind, Inc., Director at Semprus BioSciences Corp., Director at Selecta Biosciences, Inc., Director at Kala Pharmaceuticals, Inc., Director at SQZ Biotechnologies Co., Director at Microchips Biotech, Inc., Director at T2 Biosystems, Inc., Director at Lyra Therapeutics, Inc., Director at Tarveda Therapeutics, Inc. and Director at Sigilon Therapeutics, Inc.
Robert S. Langer received an undergraduate degree from Cornell University and a doctorate from Massachusetts Institute of Technology.
|
Current positions of Robert Langer | |
|
Name | Title |
Since |
Moderna, Inc. (Biotechnology & Medical Research) |
Independent Non-Executive Director |
2010 | PureTech Health plc (Biotechnology & Medical Research) |
Non-Executive Director |
2015 | Abpro Bio Co., Ltd. (Industrial Machinery & Equipment) |
Director |
2020 | Seer, Inc. (Office Equipment) |
Director |
2017 | N2Tech Co.,Ltd (Semiconductor Equipment & Testing) |
Director |
- | Abpro Corporation
|
Director |
2016 | TARA Biosystems, Inc. |
Director |
2016 | Arsenal Medical, Inc. |
Director |
2011 | Aris Pharmaceuticals, Inc. |
Director |
- | Lyndra Therapeutics, Inc. |
Director |
2015 | Luminopia, Inc. |
Director |
- | EpiBone, Inc. |
Director |
2020 | Verseau Therapeutics, Inc. |
Director |
2017 | Suono Bio, Inc. |
Director |
- | Alivio Therapeutics, Inc. |
Director |
- | Glympse Bio, Inc. |
Director |
- | LikeMinds, Inc. (Massachusetts) |
Director |
- | Xenter, Inc. |
Director |
2021 | Bilayer Therapeutics, Inc. |
Director |
- | Syntis Bio, Inc. |
Director |
- | Noveome Biotherapeutics, Inc. |
Director |
- | Micell Technologies, Inc. |
Director |
- | Humacyte Global, Inc. |
Director |
2008 | TARIS BioMedical LLC |
Director |
2008 | YourBio Health, Inc. |
Director |
2008 | StemBioSys, Inc. |
Director |
- | Cornell University |
Director |
- | The Children's Hospital Corp. |
Trustee |
- | Puretech Health LLC |
Co-Founder & Non-Executive Director |
2000 | Whitehead Institute for Biomedical Research |
Director |
- | Entrega, Inc. |
Director |
- | Golub & Co. LLC |
Director |
- | Healthcare Royalty Management LLC |
Board Member |
2013 | The Children's Medical Center Corp. |
Trustee |
- | CHS Pharma, Inc. |
Director |
2013 | XTuit Pharmaceuticals, Inc. |
Director |
2011 | Massachusetts Institute of Technology |
Professor |
2005 | David H. Koch Institute for Integrative Cancer Research |
Professor |
2005 | aMoon Ventures Y Sh Ltd. |
Advisor |
- | Olivo Laboratories LLC |
Co-Founder |
- | KensaGroup LLC |
Scientific Advisory Board |
- | Eagle Biologics, Inc. |
Co-Founder |
2013 |
|
Holdings of Robert Langer | |
|
Name | Equities | % | Valuation |
Moderna, Inc. (MRNA) (Biotechnology & Medical Research) | 11,509,357 | 3.02% | 874,250,758 USD |
PureTech Health plc (PRTC) (Biotechnology & Medical Research) | 2,955,324 | 1.08% | 5,436,584 USD |
Seer, Inc. (SEER) (Office Equipment) | 725,847 | 1.21% | 1,190,389 USD |
Korro Bio, Inc. (KRRO) (Biotechnology & Medical Research) | 214,326 | 0.59% | 51,438 USD |
|
Robert Langer : Personal Network | |
|
Name | Linked companies |
Terrance G. McGuire | Seer, Inc. Whitehead Institute for Biomedical Research David H. Koch Institute for Integrative Cancer Research Arsenal Medical, Inc. |
Paula Hammond | Moderna, Inc. Massachusetts Institute of Technology David H. Koch Institute for Integrative Cancer Research |
Noubar Afeyan | Moderna, Inc. Massachusetts Institute of Technology YourBio Health, Inc. |
Eric Elenko | PureTech Health plc Alivio Therapeutics, Inc. Puretech Health LLC |
Phillip A. Sharp | David H. Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Whitehead Institute for Biomedical Research |
John L. LaMattina | PureTech Health plc Alivio Therapeutics, Inc. Puretech Health LLC |
Kiran Mazumdar Shaw | PureTech Health plc Massachusetts Institute of Technology Puretech Health LLC |
Amy Schulman | Glympse Bio, Inc. Suono Bio, Inc. Eagle Biologics, Inc. Olivo Laboratories LLC Lyndra Therapeutics, Inc. Whitehead Institute for Biomedical Research |
Daphne Zohar | PureTech Health plc Puretech Health LLC Whitehead Institute for Biomedical Research |
Andrew Miller | PureTech Health plc Entrega, Inc. Puretech Health LLC |
|
© 2023 People and Ownership :
|
Robert Langer : Connections | |
|
|
Latest news about Robert Langer | |
|
10/24 | Transcript : Alexandria Real Estate Equities, Inc., Q3 2023 Earnings Call, Oct 24, 2023 | CI |
06/21 | Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women | CI |
02/13 | Frequency Therapeutics, Inc. Appoints Christopher Loose, Ph.D., as Interim Chief Executive Officer | CI |
01/26 | Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause | CI |
01/12 | Transcript : Establishment Labs Holdings Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 07:30 AM | CI |
01/09 | Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study | CI |
2022 | Transcript : Establishment Labs Holdings Inc., Q3 2022 Earnings Call, Nov 07, 2022 | CI |
|
|